A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Therapeutic targeting of advanced or metastatic non-small-cell lung cancer (NSCLC) represents a major goal of clinical treatment. Polo-like kinase 1 (PLK1) is an essential mitotic kinase in cell cycle progression and is associated with oncogenesis in a large spectrum of cancer types, including NSCLC. Volasertib (BI 6727) is a potent, selective, PLK1 inhibitor that is currently under phase 2 clinical trials with modest antitumor activity against solid tumors. As the combination of volasertib with pemetrexed does not improve efficacy for NSCLC treatment, it is crucial to identify compounds that could enhance efficacy with volasertib. Immunomodulatory drugs (IMiDs) bind to E3 ligase CRBN and repurposes it to ubiquitinate other proteins as neo-substrates, representing an effective treatment for hematologic malignancies. In this study, by screening IMiDs, we found that a novel CRBN modulator, CC-885, can synergistically inhibit NSCLC with volasertib both in vitro and in vivo . This synergistic effect overcomes volasertib resistance caused by PLK1 mutations and is compromised in CRBN-or p97-depleted cells. Mechanistically, CC-885 selectively promotes CRBN- and p97-dependent PLK1 ubiquitination and degradation, thereby enhancing the sensitivity of NSCLC to volasertib. In conclusion, our findings reveal that PLK1 is a neo-substrate of CUL4-CRBN induced by CC-885 and represent a combinational approach for treating NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879 · cited 2×
“For example, the clinical activity of IMiDs in multiple myeloma is achieved by selective degradationof IKZF1and IKZF3.(19,20)Thedegradationof casein1aprotein kinase (CK1a) is considered the key mechanism of IMiDs in the treatment of the deletion 5q (del(5q)) subtype of myelodysplastic syndrome (MDS).”
BackgroundInfluentialThe Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature · doi:10.1038/nature14610 · Cited by 863 · cited 1×
“Thedegradationof casein1aprotein kinase (CK1a) is considered the key mechanism of IMiDs in the treatment of the deletion 5q (del(5q)) subtype of myelodysplastic syndrome (MDS).(21) A new CRBN modulator, CC-885, has recently been identified.”
BackgroundA novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
Matyskiela, M. E., Lu, G., Ito, T., Pagarigan, B., Lu, C.-C., Miller, K., Fang, W., Wang, N.-Y., Nguyen, D., Houston, J., et al. (2016) · Nature · doi:10.1038/nature18611 · Cited by 701 · cited 13×
“Volasertib and CC-885 CC-885 is a recently identified novel CRBN modulator.(22) Similar to lenalidomide and its analogs, CC-885 contains a glutarimide ring that can directly interact with CRBN (Figure 1B), and cells without CRBN were resistant to CC-885 treatment.”
BackgroundInfluentialShared and separate functions of polo-like kinases and aurora kinases in cancer
Lens, S. M. A., Voest, E. E., & Medema, R. H. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2964 · Cited by 597 · cited 1×
“The polo-like kinase (PLK) family members are serine/threonine protein kinases, which regulate many steps of the cell cycle.(6) This family has five members: PLK1, PLK2, PLK3, PLK4, and PLK5.”
BackgroundPharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
Olson, C. M., Jiang, B., Erb, M. A., Liang, Y., Doctor, Z. M., Zhang, Z., Zhang, T., Kwiatkowski, N., Boukhali, M., Green, J. L., et al. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2538 · Cited by 552 · cited 2×
“For example, Olson et al.(30) revealed that cyclin-dependent kinase 9 (CDK9) degradation can induce distinct pharmacological effects compared to its inhibition.”
BackgroundDefining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
Sievers, Q. L., Petzold, G., Bunker, R. D., Renneville, A., Słabicki, M., Liddicoat, B. J., Abdulrahman, W., Mikkelsen, T., Ebert, B. L., & Thomä, N. H. (2018) · Science · doi:10.1126/science.aat0572 · Cited by 537
Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics
Gutteridge, R. E. A., Ndiaye, M. A., Liu, X., & Ahmad, N. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0897 · Cited by 406
p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates
Nguyen, T. V., Li, J., Lu, C.-C. (., Mamrosh, J. L., Lu, G., Cathers, B. E., & Deshaies, R. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700949114 · Cited by 85
Cited by
From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation
Oleinikovas, V., Gainza, P., Ryckmans, T., Fasching, B., & Thomä, N. H. (2024) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022123-104147 · Cited by 178
Haven't got a glue: Protein surface variation for the design of molecular glue degraders
Kozicka, Z., & Thomä, N. H. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.009 · Cited by 170
A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer
Lier, S., Sellmer, A., Orben, F., Heinzlmeir, S., Krauß, L., Schneeweis, C., Hassan, Z., Schneider, C., Patricia Gloria Schäfer, A., Pongratz, H., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105505 · Cited by 37
From serendipity to strategy: molecular glue degraders in cancer therapeutics
Darling, S., Bajrami, I., & West, S. C. (2025) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2025.2564068 · Cited by 9
“PROtAcs targeting PlK1, BtK, BRAF (v600e) and NtRK have exhibited promising pre-clinical and clinical success across a range of cancers (li et al. 2020; lier et al. 2022; Zhong et al. 2024).”
Metadata
- Authors
- Li, L., Xue, W., Shen, Z., Liu, J., Hu, M., Cheng, Z., Wang, Y., Chen, Y., Chang, H., Liu, Y., Liu, B., & Zhao, J.
- Venue
- Molecular Therapy - Oncolytics
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 18
- Pages
- 215-225
- ISSN
- 2372-7705 (ISSN-L)
- OpenAlex
- W3037072276
- Cited by
- 40
- References
- 10
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer. https://app.cochat.ai/papers/10.1016/j.omto.2020.06.013
- The paper
- Li, L., Xue, W., Shen, Z., Liu, J., Hu, M., Cheng, Z., Wang, Y., Chen, Y., Chang, H., Liu, Y., Liu, B., & Zhao, J. (2020). A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer. Molecular Therapy - Oncolytics. https://doi.org/10.1016/j.omto.2020.06.013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.